



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	September 10, 2010 April 5, 2012, November 9, 2015

## **Aloxi® (palonosetron)**

**LENGTH OF AUTHORIZATION:** Up to one year

**APPROVAL INDICATIONS:**

- Documented failure of ondansetron via progress/chart notes.
- Diagnosis of nausea and vomiting verified via patient health conditions or progress notes.

**DOSING:**

**PEDIATRICS** (1month to <17 years old): A single dose of 20mcg/kg (max of 1.5mg) intravenously (IV) over 15 minutes beginning approximately 30 minutes before the start of chemotherapy.

**ADULTS:**

For the prevention of cancer chemotherapy-induced nausea and vomiting in adults, a single palonosetron dose of 0.25 mg (administered IV over 30 seconds) is given approximately 30 minutes before the start of chemotherapy. Because the safety and efficacy of a repeat dose (e.g., on consecutive or alternate days) of palonosetron have not been established, administration of an additional dose of the drug within a 7-day period currently is *not* recommended.

For the prevention of postoperative nausea and vomiting, a single palonosetron dose of 0.075mg administered IV over 10 seconds immediately before induction of anesthesia.

**LIMITS:** 40ml every 28 days